RxDoctor Payments Data

Robert Daniels, MD

Family Medicine · Glen Allen, VANPI 1922069889

Payments from drug & device makers

$11,804in general payments, 2019–2025

Across 712 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Amgen$999
  • Pfizer$860
  • Lilly USA, LLC$689
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$11,788100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,804 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$165,468
Medicare patients
361
Services billed
4,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide55$115,946
FarxigaDapagliflozin Propanediol94$115,155
JardianceEmpagliflozin61$89,383
OzempicSemaglutide11$15,593
Atorvastatin Calcium722$5,899
SynthroidLevothyroxine Sodium36$4,653
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,814
Rosuvastatin Calcium188$2,505
Metoprolol Succinate133$2,103
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide59$2,075
Ezetimibe84$1,860
Fenofibrate61$1,802
Duloxetine Hcl42$1,562
Levothyroxine Sodium133$1,460
Losartan Potassium192$1,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$689$115,94655 claims
AstraZenecaFarxiga$1,079$115,15594 claims
Boehringer IngelheimJardiance$331$89,38361 claims
Novo NordiskOzempic$1,307$15,59311 claims
AbbVieSynthroid$1,526$4,65336 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$108$1,460133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Glen Allen

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →